Sumitomo Pharma Co Debt 2024

Sumitomo Pharma Co Aktienanalyse

What does Sumitomo Pharma Co do?

Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Sumitomo Pharma Co's Debt Structure

Sumitomo Pharma Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Sumitomo Pharma Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Sumitomo Pharma Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Sumitomo Pharma Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Sumitomo Pharma Co stock

What is the debt of Sumitomo Pharma Co this year?

Sumitomo Pharma Co has a debt level of 399,916 JPY this year.

What was the debt of Sumitomo Pharma Co compared to the previous year?

The debt of Sumitomo Pharma Co has increased by 385.44% compared to the previous year increased.

What are the consequences of high debt for investors in Sumitomo Pharma Co?

High debt can pose a risk for investors of Sumitomo Pharma Co, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Sumitomo Pharma Co?

Low debt means that Sumitomo Pharma Co has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Sumitomo Pharma Co affect the company?

An increase in debt of Sumitomo Pharma Co can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Sumitomo Pharma Co affect the company?

A reduction in debt of Sumitomo Pharma Co can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Sumitomo Pharma Co?

Some factors that can influence the debt of Sumitomo Pharma Co include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Sumitomo Pharma Co so important for investors?

The debts of Sumitomo Pharma Co are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Sumitomo Pharma Co take to change the debt?

To change the debt, Sumitomo Pharma Co can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Sumitomo Pharma Co pay?

Over the past 12 months, Sumitomo Pharma Co paid a dividend of 14 JPY . This corresponds to a dividend yield of about 2.33 %. For the coming 12 months, Sumitomo Pharma Co is expected to pay a dividend of 14 JPY.

What is the dividend yield of Sumitomo Pharma Co?

The current dividend yield of Sumitomo Pharma Co is 2.33 %.

When does Sumitomo Pharma Co pay dividends?

Sumitomo Pharma Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Sumitomo Pharma Co?

Sumitomo Pharma Co paid dividends every year for the past 0 years.

What is the dividend of Sumitomo Pharma Co?

For the upcoming 12 months, dividends amounting to 14 JPY are expected. This corresponds to a dividend yield of 2.33 %.

In which sector is Sumitomo Pharma Co located?

Sumitomo Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sumitomo Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sumitomo Pharma Co from 6/1/2023 amounting to 7 JPY, you needed to have the stock in your portfolio before the ex-date on 3/30/2023.

When did Sumitomo Pharma Co pay the last dividend?

The last dividend was paid out on 6/1/2023.

What was the dividend of Sumitomo Pharma Co in the year 2023?

In the year 2023, Sumitomo Pharma Co distributed 28 JPY as dividends.

In which currency does Sumitomo Pharma Co pay out the dividend?

The dividends of Sumitomo Pharma Co are distributed in JPY.